Zynlonta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing incidence of hematological malignancies, rising failure rates of conventional chemotherapy, expansion of oncology specialty centers, improved diagnostic capabilities for lymphoma subtypes, growing clinical adoption of adc therapies.

The growth in the forecast period can be attributed to increasing development of next-generation adcs, rising demand for personalized cancer treatment, expansion of targeted oncology pipelines, growing investments in biologic cancer drugs, increasing use of combination cancer therapies. Major trends in the forecast period include increasing adoption of antibody-drug conjugate therapies, rising use of targeted treatments for b-cell lymphomas, growing focus on precision oncology drugs, expansion of hospital-based oncology infusion services, enhanced emphasis on relapsed and refractory cancer treatments.

The rising incidence of lymphomas is expected to drive the growth of the Zynlonta market in the coming years. Lymphomas are cancers originating in the lymphatic system that primarily affect lymphocytes, a type of white blood cell present in lymph nodes, the spleen, bone marrow, and other lymphoid tissues. The rising incidence of lymphomas is attributed to factors such as an aging population, immune system suppression, environmental exposures, viral infections, genetic predisposition, and lifestyle choices. Zynlonta is a targeted therapy for relapsed or refractory large B-cell lymphoma (LBCL), delivering a chemotherapy agent directly to cancerous B cells, effectively killing them. For instance, according to the American Cancer Society, a US-based non-profit organization, the estimated number of new lymphoma cases increased from 89,010 in 2022 to 89,380 in 2023. Therefore, the rising incidence of lymphomas is driving the growth of the Zynlonta market.

The rise in clinical trials is expected to propel the growth of the Zynlonta market. Clinical trials are research studies involving human participants to evaluate the safety, efficacy, and effectiveness of medical interventions, including drugs, devices, procedures, or diagnostic tools. The increase in clinical trials is driven by the growing demand for new treatments, advancements in medical research, and the need to address emerging health challenges. Clinical trials support Zynlonta by generating robust evidence that demonstrates its safety and efficacy, aiding regulatory approvals and fostering physician confidence. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI), a UK-based organization, reported that the number of pharmaceutical industry trials launched in the UK rose for the second consecutive year, increasing from 411 in 2022 to 426 in 2023, representing a 3.7% rise in registered trials. Therefore, the rise in clinical trials is driving the growth of the Zynlonta market.

A key trend in the Zynlonta market is the development of innovative therapies, such as combination therapies, to enhance treatment efficacy and improve patient outcomes in cancer care. Combination therapies involve using two or more treatments, such as drugs or therapeutic approaches, to target multiple aspects of a disease and improve overall effectiveness. For instance, in April 2024, ADC Therapeutics, a Switzerland-based biotechnology company specializing in antibody-drug conjugates (ADCs) for hematological malignancies and solid tumors, announced updates on the LOTIS-7 clinical trial. This trial evaluates Zynlonta (loncastuximab tesirine-lpyl) in combination with bispecific antibodies, including glofitamab and mosunetuzumab, for heavily pretreated patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL).

Major companies operating in the zynlonta market are ADC Therapeutics SA, Avid Bioservices Inc.

North America was the largest region in the zynlonta market in 2025. The regions covered in the zynlonta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zynlonta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the zynlonta market by increasing costs of imported cytotoxic payloads, monoclonal antibody components, specialized manufacturing equipment, and cold-chain logistics systems. Oncology treatment centers in North America and Europe are most affected due to dependence on globally sourced biologic inputs, while Asia-Pacific faces higher costs for adc imports. These tariffs elevate treatment pricing and strain hospital oncology budgets. At the same time, they are encouraging domestic adc manufacturing, regional clinical supply chains, and investments in localized biologics production infrastructure.

The zynlonta market research report is one of a series of new reports that provides zynlonta market statistics, including zynlonta industry global market size, regional shares, competitors with a zynlonta market share, detailed zynlonta market segments, market trends and opportunities, and any further data you may need to thrive in the zynlonta industry. This zynlonta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zynlonta (loncastuximab tesirine-lpyl) is a prescription oncology medication and a targeted therapy classified as an antibody-drug conjugate (ADC). It is indicated for the treatment of relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL), in patients who have received two or more lines of systemic therapy.

The primary indications for Zynlonta are diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL) characterized by the rapid proliferation of large B-cells in the lymphatic system, typically managed with chemotherapy and immunotherapy such as rituximab. Zynlonta is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, serving adult and elderly patients.

The zynlonta market consists of sales of combination therapies, diagnostic and companion tools, supportive care medications, injection kits, and biosimilars. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.